BURLINGTON, Mass., Feb. 24 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9^th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention. InfraReDx will be displaying its novel LipiScan™ Coronary Imaging System at booth #306 throughout the LUMEN meeting. InfraReDx will be available to discuss with attending clinical and interventional cardiologists, cardiac and vascular surgeons and other cardiovascular professionals LipiScan's abilities in identifying and characterizing lipid core (fatty) plaques and the importance of this novel technology.

InfraReDx's LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. Lipid core-containing plaque (LCP) is believed to be "vulnerable plaque" that can rupture and form dangerous blood clots leading to coronary thrombosis.  LCP is widely considered to be responsible for a significant number of stenting procedure complications and is believed to be the primary cause of acute coronary events, the leading cause of death in the developed world.

LUMEN 2010 marks the third key educational symposium that the Company has participated in over the past month. InfraReDx was an active speaking and panel participant during the recent Cardiovascular Research Technologies (CRT) annual meeting in Washington, D.C., and live case demonstrations of the LipiScan system were a highlight of the Scottsdale Interventional Forum in Scottsdale, Arizona, earlier this month. InfraReDx will continue to showcase LipiScan at upcoming events and medical meetings, including the 59^th Annual Scientific Sessions of the American College of Cardiology (ACC), taking place March 14-16 in Atlanta.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.  

About LUMEN 2010

LUMEN 2010 enables productive peer-to-peer discussions pertaining to establishing the best practices in the treatment of acute MI patients, including diagnosis and treatment options, giving them the practical knowledge, tools, and insight they need to improve patient care and quality of life. LUMEN 2010 will benefit clinical and interventional cardiologists, cardiac and vascular surgeons, emergency department staff, critical care nurses, cardiovascular laboratory technologists and nurses, paramedics, emergency medical technicians, and hospital administrators. For more information, please visit www.lumenami.com.

SOURCE InfraReDx, Inc.

Back to top

RELATED LINKS
http://www.infraredx.com